Revance Therapeutics Receives $96,000,000 New Funding Round

  • Feed Type
  • Date
    2/6/2014
  • Company Name
    Revance Therapeutics
  • Mailing Address
    7555 Gateway Boulevard Newark, CA 94560
  • Company Description
    Revance (NASDAQ: RVNC) is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin.
  • Website
    http://www.revance.com
  • Transaction Type
    IPO
  • Transaction Amount
    $96,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes are on file with company statements at the SEC.
  • M&A Terms

By posting a comment, you agree to our terms and conditions.